​

Biohaven (BHVN) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChart

BHVN Stock Forecast

Biohaven (BHVN) stock forecast, based on 25 Wall Street analysts, predicts a 12-month average price target of $24.67, with a high of $48.00 and a low of $11.00. This represents a 70.37% increase from the last price of $14.48.

$5 $14 $23 $32 $41 $50 High: $48 Avg: $24.67 Low: $11 Last Closed Price: $14.48

BHVN Stock Rating

Biohaven stock's rating consensus is Buy, based on 25 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 16 Buy (64.00%), 8 Hold (32.00%), 1 Sell (4.00%), and 0 Strong Sell (0.00%).

Buy
Total 25 1 8 16 Strong Sell Sell Hold Buy Strong Buy

BHVN Price Target Upside V Benchmarks

TypeNameUpside
StockBiohaven70.37%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts1514
Avg Price Target$48.00$27.40$20.29
Last Closing Price$14.48$14.48$14.48
Upside/Downside231.49%89.23%40.12%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Nov, 26394-117
Oct, 26394-117
Sep, 26492-116
Aug, 26493-117
Jul, 264104-119
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 22, 2026Brian SkorneyRobert W. Baird$48.00$15.02219.57%231.49%
Sep 08, 2026Leonid TimashevRBC Capital$19.00$15.6921.10%31.22%
Aug 28, 2026Sumant KulkarniCanaccord Genuity$21.00$16.1130.35%45.03%
Aug 26, 2026Chris RaymondRaymond James$30.00$16.4782.15%107.18%
Aug 12, 2026Morgan Stanley$19.00$14.4931.12%31.22%
Jun 29, 2026Needham$11.00$15.83-30.51%-24.03%
May 13, 2026Terence FlynnMorgan Stanley$18.00$8.93101.57%24.31%
Mar 04, 2026Douglas TsaoH.C. Wainwright$10.00$10.39-3.75%-30.94%
Mar 03, 2026Marc GoodmanLeerink Partners$15.00$10.6740.58%3.59%
Feb 05, 2026Goldman Sachs$23.00$10.76113.75%58.84%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Oct 23, 2026RBC CapitalSector PerformSector Performhold
Oct 08, 2026Raymond JamesStrong BuyStrong Buyhold
Sep 18, 2026CitigroupBuyBuyhold
Sep 08, 2026RBC CapitalOutperformSector Performdowngrade
Aug 27, 2026H.C. WainwrightNeutralNeutralhold
Aug 26, 2026Cowen & Co.BuyBuyhold
Aug 26, 2026Raymond JamesStrong BuyStrong Buyhold
Aug 12, 2026Morgan StanleyOverweightOverweighthold
Aug 11, 2026RBC CapitalOutperformOutperformhold
Jun 29, 2026Bank of America SecuritiesBuyUnderperformdowngrade

Financial Forecast

EPS Forecast

$-25 $-20 $-15 $-10 $-5 $0 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-5.97$-12.75$-5.73$-9.28$-6.86---
Avg Forecast$-7.31$-9.79$-5.22$-9.01$-6.36$-5.57$-4.11$-1.78
High Forecast$-5.85$-0.41$-5.00$-8.11$-5.49$-3.72$-1.29$-0.08
Low Forecast$-8.77$-22.52$-5.45$-9.94$-7.27$-7.15$-6.30$-4.10
Surprise %-18.33%30.23%9.77%3.00%7.86%---

Revenue Forecast

$0 $400M $800M $1B $2B $2B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported--------
Avg Forecast$426.10M$820.28M-$7.69M$18.54M$154.46M$501.96M$898.51M
High Forecast$511.32M$984.33M-$15.39M$37.10M$309.07M$510.22M$1.80B
Low Forecast$340.88M$656.22M-$2.03M$4.88M$40.67M$493.70M$236.60M
Surprise %--------

Net Income Forecast

$-850M $-680M $-510M $-340M $-170M $0 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-213.80M$-570.28M$-408.17M$-846.42M$-738.82M---
Avg Forecast$-596.80M$-620.81M$-408.17M$-642.41M$-454.23M$-386.92M$-270.35M$-126.97M
High Forecast$-477.44M$-496.65M$-326.53M$-577.16M$-391.03M$-265.06M$-91.93M$-5.37M
Low Forecast$-716.16M$-744.97M$-489.80M$-707.67M$-517.43M$-508.79M$-448.78M$-292.19M
Surprise %-64.18%-8.14%-31.76%62.65%---

BHVN Forecast FAQ

Is Biohaven stock a buy?

Biohaven stock has a consensus rating of Buy, based on 25 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 16 Buy, 8 Hold, 1 Sell, and 0 Strong Sell, reflecting a consensus that Biohaven is a favorable investment for most analysts.

What is Biohaven's price target?

Biohaven's price target, set by 25 Wall Street analysts, averages $24.67 over the next 12 months. The price target range spans from $11 at the low end to $48 at the high end, suggesting a potential 70.37% change from the previous closing price of $14.48.

How does Biohaven stock forecast compare to its benchmarks?

Biohaven's stock forecast shows a 70.37% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Biohaven over the past three months?

  • November 2026: 17.65% Strong Buy, 52.94% Buy, 23.53% Hold, 0% Sell, 5.88% Strong Sell.
  • October 2026: 17.65% Strong Buy, 52.94% Buy, 23.53% Hold, 0% Sell, 5.88% Strong Sell.
  • September 2026: 25.00% Strong Buy, 56.25% Buy, 12.50% Hold, 0% Sell, 6.25% Strong Sell.

What is Biohaven’s EPS forecast?

Biohaven's average annual EPS forecast for its fiscal year ending in December 2026 is $-5.57, marking a -18.80% decrease from the reported $-6.86 in 2025. Estimates for the following years are $-4.11 in 2027, and $-1.78 in 2028.

What is Biohaven’s revenue forecast?

Biohaven's average annual revenue forecast for its fiscal year ending in December 2026 is $154.46M, reflecting a 0% decrease from the reported $0 in 2025. The forecast for 2027 is $501.96M, and $898.51M for 2028.

What is Biohaven’s net income forecast?

Biohaven's net income forecast for the fiscal year ending in December 2026 stands at $-387M, representing a -47.63% decrease from the reported $-739M in 2025. Projections indicate $-270M in 2027, and $-127M in 2028.